MedPath

Telemedicine vs. Face-to-Face Cancer Genetic Counseling

Not Applicable
Completed
Conditions
Hereditary Breast and Ovarian Cancer Syndrome
Lynch Syndrome
Registration Number
NCT00609505
Lead Sponsor
Duke University
Brief Summary

Cancer genetic counseling (CGC) has been found to have "substantial" benefits for individuals with breast cancer and their family members; it has been deemed by multiple organizations as "standard of care" for women with breast cancer and their relatives. Unfortunately, there is a disparity in access to CGC, especially among women who live in rural and underserved areas. In North Carolina, only two cancer genetic counselors practice in rural clinics - each only for a few days per month. Therefore, in an effort to make CGC more widely available in a timely manner, we propose to test provision of counseling through telemedicine (TM), in which a patient and health care provider communicate with each other using videoconferencing. In 4 rural oncology clinics, we will implement low-cost TM and compare satisfaction and cost-effectiveness between groups of women designated to have their CGC session by TM or FTF. We'll use a validated measure to assess satisfaction by a phone survey one week after the CGC appointment; cost-effectiveness will be measured at project's end by calculating length of wait time for appointment and costs of equipment, labor, and mileage. Study hypothesis: TM is as satisfactory as FTF counseling and is a more cost-effective way to provide this beneficial service.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
130
Inclusion Criteria
  • Individuals referred for cancer genetic counseling (e.g., by medical oncologist, primary care physician or self) in one of 4 oncology clinics: Gibson Cancer Center in Lumberton, NC; Scotland Cancer Treatment Center in Laurinburg, NC; Johnston Cancer Center in Smithfield, NC; and Maria Parham Cancer Center in Henderson, NC.
  • Willing to be randomized to receive counseling via telemedicine or face-to-face.
Exclusion Criteria
  • Referred for cancer genetic counseling from any clinic other than the 4 listed above.
  • Unwilling to be randomized to receive counseling via telemedicine or face-to-face.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Patient satisfactionOne week post-intervention (genetic counseling session)
Secondary Outcome Measures
NameTimeMethod
Cost-effectivenessEnrollment completion

Trial Locations

Locations (4)

Maria Parham Medical Center

🇺🇸

Henderson, North Carolina, United States

Scotland Cancer Treatment Center

🇺🇸

Laurinburg, North Carolina, United States

Gibson Cancer Center

🇺🇸

Lumberton, North Carolina, United States

Johnston Cancer Center

🇺🇸

Smithfield, North Carolina, United States

Maria Parham Medical Center
🇺🇸Henderson, North Carolina, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.